Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency
page end: 494
related by: authorship_16365
type: Continuant
related by: authorship_16366
related by: authorship_16356
chemicalscas: alendronic acid, 66376-36-1; alfacalcidol, 41294-56-8; alkaline phosphatase, 9001-78-9; calcitriol, 32222-06-3, 32511-63-0, 66772-14-3; calcium, 14092-94-5, 7440-70-2; creatinine, 19230-81-0, 60-27-5; ibandronic acid, 114084-78-5, 138844-81-2, 138926-19-9; raloxifene, 82640-04-8, 84449-90-1; risedronic acid, 105462-24-6, 122458-82-6; strontium ranelate, 135459-87-9; zoledronic acid, 118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7; Alendronate, 66376-36-1; Bone Density Conservation Agents; Cholecalciferol, 67-97-0; Diphosphonates; Drug Combinations
related by: authorship_16406
related by: authorship_16407
related by: authorship_16360
related by: authorship_16363
related by: authorship_16395
related by: authorship_16422
related by: authorship_16423
related by: authorship_16394
related by: authorship_16413
type: Document
related by: authorship_16426
estado: published
most specific type: Article
has publication venue: Calcified Tissue International
related by: authorship_16375
related by: authorship_16369
related by: authorship_16416
related by: authorship_16373
related by: authorship_16431
page start: 485
related by: authorship_16432
related by: authorship_16389
type: Article
most specific type: Document
related by: authorship_16383
related by: authorship_16384
related by: authorship_16364
related by: authorship_16354
related by: authorship_16355
related by: authorship_16358
type: Information Content Entity
related by: authorship_16359
related by: authorship_16398
related by: authorship_16399
related by: authorship_16405
related by: authorship_16361
related by: authorship_16362
related by: authorship_16352
related by: authorship_16420
related by: authorship_16421
related by: authorship_16392
related by: authorship_16411
related by: authorship_16393
related by: authorship_16412
related by: authorship_16415
origen: scopus
issue: 6
abstract: Vitamin D insufficiency is common in patients with osteoporosis. We conducted a randomized trial comparing alendronate 70 mg combined with vitamin D3 5,600 IU in a single tablet (ALN/D5600, n = 257) with standard care chosen by the patients' personal physicians (n = 258) in patients with postmenopausal osteoporosis (BMD T score ≤2.5 or ≤1.5 and a prior fragility fracture) who had vitamin D insufficiency (serum 25[OH]D values 8-20 ng/ml) and who were at risk of falls. Virtually all patients randomized to standard care received bisphosphonate therapy, and in approximately 70%25 of cases this was combined with vitamin D supplements. However, only 24%25 took ≥800 IU/day of supplemental vitamin D. At 6 months the proportion of patients with vitamin D insufficiency was 8.6%25 in the ALN/D5600 group compared with 31.0%25 in the standard care group (P < 0.001). Those in the ALN/D5600 group also had a greater reduction in urinary NTX/creatinine ratio (-57%25 vs. -46%25, P < 0.001) and bone-specific alkaline phosphatase (-47%25 vs. -40%25, P < 0.001). In the ALN/5600 group, by 12 months the increase in BMD was greater at the lumbar spine (4.9%25 vs. 3.9%25, P = 0.047) and the total hip (2.2%25 vs. 1.4%25, P = 0.035), significantly fewer patients were vitamin D-insufficient (11.3%25 vs. 36.9%25, P < 0.001), and bone turnover marker (BTM) results were similar to those at 6 months. There was no difference between groups in those who experienced falls or fractures, and adverse events were similar. Based on the finding that ALN/D5600 was more effective than standard care at correcting vitamin D insufficiency, increasing BMD, and reducing BTMs in this patient group, greater attention needs to be directed toward optimizing the treatment of osteoporosis and correcting vitamin D deficiency in postmenopausal women. © 2011 Springer Science%2bBusiness Media, LLC.
related by: authorship_16430
e iscopus: 2-s2.0-79959744770
type: Generically Dependent Continuant
related by: authorship_16387
related by: authorship_16388
related by: authorship_16378
related by: authorship_16379
related by: authorship_16401
related by: authorship_16382
date time value: article date 2785
related by: authorship_16400
related by: authorship_16381
related by: authorship_16428
related by: authorship_16419
related by: authorship_16429
related by: authorship_16372
related by: authorship_16385
related by: authorship_16404
freetext keyword: Alendronate; Bone mineral density; Bone turnover marker; Osteoporosis; Vitamin D alendronic acid; alendronic acid plus colecalciferol; alfacalcidol; alkaline phosphatase; amino terminal telopeptide; calcitriol; calcium; creatinine; ibandronic acid; raloxifene; risedronic acid; strontium ranelate; vitamin D; zoledronic acid; aged; article; bone density; bone turnover; controlled study; diarrhea; drug efficacy; drug fatality; drug safety; drug tolerability; drug withdrawal; falling; female; health care quality; heart atrium fibrillation; human; major clinical study; multicenter study; postmenopause osteoporosis; priority journal; protein urine level; randomized controlled trial; risk assessment; stomach ulcer; vitamin blood level; vitamin D deficiency; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Drug Combinations; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Standard of Care; Vitamin D Deficiency
related by: authorship_16353
related by: authorship_16357
volume: 88
related by: authorship_16397
type: Entity
abstract: Vitamin D insufficiency is common in patients with osteoporosis. We conducted a randomized trial comparing alendronate 70 mg combined with vitamin D3 5,600 IU in a single tablet (ALN/D5600, n = 257) with standard care chosen by the patients%27 personal physicians (n = 258) in patients with postmenopausal osteoporosis (BMD T score ≤2.5 or ≤1.5 and a prior fragility fracture) who had vitamin D insufficiency (serum 25[OH]D values 8-20 ng/ml) and who were at risk of falls. Virtually all patients randomized to standard care received bisphosphonate therapy, and in approximately 70%25 of cases this was combined with vitamin D supplements. However, only 24%25 took ≥800 IU/day of supplemental vitamin D. At 6 months the proportion of patients with vitamin D insufficiency was 8.6%25 in the ALN/D5600 group compared with 31.0%25 in the standard care group (P < 0.001). Those in the ALN/D5600 group also had a greater reduction in urinary NTX/creatinine ratio (-57%25 vs. -46%25, P < 0.001) and bone-specific alkaline phosphatase (-47%25 vs. -40%25, P < 0.001). In the ALN/5600 group, by 12 months the increase in BMD was greater at the lumbar spine (4.9%25 vs. 3.9%25, P = 0.047) and the total hip (2.2%25 vs. 1.4%25, P = 0.035), significantly fewer patients were vitamin D-insufficient (11.3%25 vs. 36.9%25, P < 0.001), and bone turnover marker (BTM) results were similar to those at 6 months. There was no difference between groups in those who experienced falls or fractures, and adverse events were similar. Based on the finding that ALN/D5600 was more effective than standard care at correcting vitamin D insufficiency, increasing BMD, and reducing BTMs in this patient group, greater attention needs to be directed toward optimizing the treatment of osteoporosis and correcting vitamin D deficiency in postmenopausal women. © 2011 Springer Science Business Media, LLC.

Generically Dependent Continuant
type: Class

Article
type: Class

Information Content Entity
type: Class

Calcified Tissue International
type: Periodical
type: Thing
type: Document
type: Information Content Entity
type: Journal
type: Continuant
publication venue for: Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency
type: Generically Dependent Continuant
type: Entity
type: Collection

Entity
type: Class

individual
rights: termsOfUse
date: 2026-08-24T21:50:55
publisher: vivo
type: Document
label: RDF description of Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency - http://orbis.uaslp.mx/vivo/individual/scopus2784

Document
type: Class

Continuant
type: Class